Could a One-Two punch of CAR-T and stem cell transplant beat myeloma early?

NCT ID NCT07169500

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new treatment for young adults (18-55) newly diagnosed with multiple myeloma. It uses a patient's own immune cells, engineered to attack the cancer (BCMA-CART), either alone or combined with a stem cell transplant. The goal is to see if this approach can wipe out the cancer more deeply and keep it away longer. The trial is currently recruiting 50 participants to evaluate safety and early effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BCMA-targeted CAR-T cells (a type of immune cell therapy) with or without stem cell transplant
What this could lead to: If successful, this could offer a more effective way to control multiple myeloma early on, potentially leading to longer remission periods for young patients.
What could go wrong: This is an early-phase trial with only 50 participants, so results may not apply broadly. CAR-T therapy can cause serious side effects like cytokine release syndrome, and the long-term benefits are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Institute of Hematology & Blood Diseases Hospital
RECRUITING

Tianjin, Tianjin Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.